Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights from Biogen’s (BIIB) Q3 2022 earnings results
Pharma giant Biogen Inc. (NASDAQ: BIIB) on Tuesday announced financial results for the third quarter of 2022, reporting a double-digit drop in revenues and adjusted earnings that is unchanged from the year-ago period.
Third-quarter profit, adjusted for one-off items, remained unchanged at $4.77 per share. Meanwhile, net profit more than doubled year-over-year to $1.13 billion or $7.84 per share.
Revenues decreased 10% annually to $2.51 billion during the three-month period, mainly reflecting an 11% fall in sales at the core product segment.
“We are excited about the topline results of the Clarity AD trial for lecanemab and believe this potential new therapy could provide a meaningful benefit for Alzheimer’s patients. We also continue to make progress toward delivering new impactful therapies for patients suffering from depression and SOD1 ALS, with important upcoming regulatory milestones,” said Biogen’s CEO Michel Vounatsos.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Key takeaways from Cintas’ (CTAS) third-quarter 2023 report
Cintas Corporation (NASDAQ: CTAS) has been growing its market share by diversifying into new areas and through acquisitions. The prudent business model, with a focus on recurring revenues, has helped
Here are a few points to keep in mind if you are considering Starbucks Corporation (SBUX)
Shares of Starbucks Corporation (NASDAQ: SBUX) stayed in green on Thursday. The stock has gained 10% over the past 12 months. The company delivered healthy results for its most recent
ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9%
AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter when the medical device maker's revenues increased by 9%. The company also provided guidance for fiscal
